SUPN Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

$30.40  -0.78 (-2.50%)
As of 12/03/2021 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  05/01/2012
Outstanding shares:  52,868,482
Average volume:  460,737
Market cap:   $1,648,439,269
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    868459108
ISIN:        US8684591089
Sedol:      B72ZBG4
Valuation   (See tab for details)
PE ratio:   19.65
PB ratio:   1.99
PS ratio:   2.92
Return on equity:   10.09%
Net income %:   14.49%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy